Endocrine Abstracts

First generation somatostatin receptor ligands (SRL) are the first-line drugs in primary acromegaly treatment or after surgical failure in patients with active acromegaly. In previous studies we confirmed the association of the expression of SSTR2, Ki67 and E-cadherin (CDH1) in responsive GH-secreting adenomas response to SRL. Moreover, E-cadherin showed a greater predictive capacity than most of the markers described. Loss of E-cadherin is a typical mark of ...

Context: Pathological transcriptomic landscape has been the driver of the Molecular Biology in the recent years. Massive RNA sequencing techniques have been extended from bulk RNAseq, to single cell sequencing (scRNAseq) and spot-based spatial transcriptomics (ST), and sometimes laboratory cannot afford all of them. We tried to answer the question about which would be the best option in thyroid gland using Hashimoto’s thyroiditis (HT) context.Method...

Introduction / Background: Patients with advanced GEP-NENs often present with metabolic disorders and oncological treatments may increase malnutrition risk as well as alterations on body composition. Several studies have suggested that sarcopenia is independently associated with a worse prognosis in oncological patients. Sarcopenia predicts survival regardless of body weight; moreover, a reduced muscle mass is not only observed in cachectic individuals but also in overweight p...

Since the first somatostatin receptor ligand (SRL) was used to treat acromegaly, predicting which patients could benefit from their use has become crucial to avoid months of ineffective treatment for non-responding patients. Although many biomarkers linked to SRL response have been identified, there is no consensus criterion on how to prescribe according to biomarker levels. In this study, we evaluate previously reported biomarkers using more exhaustive and accurate methods th...

Purpose: To evaluate the prevalence of autonomous cortisol secretion (ACS) in patients with primary aldosteronism (PA) and its implications on cardiometabolic and surgical outcomes.Methods: A retrospective multicenter study of PA patients who underwent 1mg-dexamethasone suppression test (DST) in follow-up in 21 Spanish tertiary hospitals. ACS was defined as a cortisol post-DST >1.8μg/dL (confirmed ACS if >5μg/dL and possible ACS if between 1.8-...

We previously described a short version of the acute octreotide test (sAOT) for predicting somatostatin receptor ligands (SRLs) response in patients with acromegaly1. In the present work, we prospectively reassess the sAOT ability to identify SRLs response in patients from the ACROFAST study using the current GH standards and control criteria and we also correlate sAOT values with E-cadherin tumor expression. Methods: Patients from the ACROFAS...

Aim: To investigate the impact of pituitary surgery on glucose metabolism and to identify predictors of diabetes remission after surgery in patients with acromegaly.Methods: A national multicenter retrospective study of acromegaly patients undergoing transsphenoidal surgery for the first time at 33 tertiary Spanish hospitals (ACRO-SPAIN study, n=604) was performed. Surgical remission was evaluated according to the 2000 and 2010 criteria. Glucose...